University of Dundee Interferon lambda 4 impacts the genetic diversity of hepatitis C virus

Hepatitis C virus (HCV) is a highly variable pathogen that frequently establishes chronic infection. This genetic variability is affected by the adaptive immune response but the contribution of other host factors is unclear. Here, we examined the role played by interferon lambda-4 (IFN-l4) on HCV diversity; IFN-l4 plays a crucial role in spontaneous clearance or establishment of chronicity following acute infection. We performed viral genome-wide association studies using human and viral data from 485 patients of white ancestry infected with HCV genotype 3a. We demonstrate that combinations of host genetic variants, which determine IFN-l4 protein production and activity, influence amino acid variation across the viral polyprotein not restricted to specific viral proteins or HLA restricted epitopes and modulate viral load. We also observed an association with viral di-nucleotide proportions. These results support a direct role for IFN-l4 in exerting selective pressure across the viral genome, possibly by a novel mechanism. DOI: https://doi.org/10.7554/eLife.42463.001

[1]  A. Tarr,et al.  Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection , 2019, Hepatology.

[2]  David Smith,et al.  Interpreting Viral Deep Sequencing Data with GLUE , 2019, Viruses.

[3]  S. Tishkoff,et al.  A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages , 2018, bioRxiv.

[4]  C. Spencer,et al.  Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus , 2017 .

[5]  G. Gerold,et al.  The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy , 2017, Journal of immunology research.

[6]  B. Walker,et al.  HLA-B*57 and IFNL4-Related Polymorphisms Are Associated With Protection Against HIV-1 Disease Progression in Controllers , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  B. Pierce,et al.  Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design , 2016, Proceedings of the National Academy of Sciences.

[8]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[9]  X. Didelot,et al.  Bayesian Inference of the Evolution of a Phenotype Distribution on a Phylogenetic Tree , 2016, Genetics.

[10]  J. Miquel,et al.  Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes Virus. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[12]  P. Klenerman,et al.  The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design , 2015, Gut.

[13]  H. Drummer,et al.  Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection , 2015, PLoS ONE.

[14]  D. Gatherer,et al.  Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[15]  H. Nomura,et al.  Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection , 2015, Journal of Gastroenterology.

[16]  Z. Kutalik,et al.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[17]  D. Tyrrell,et al.  Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. , 2014, The Journal of infectious diseases.

[18]  A. Tarr,et al.  The past, present and future of neutralizing antibodies for hepatitis C virus , 2014, Antiviral research.

[19]  Gad Abraham,et al.  Fast Principal Component Analysis of Large-Scale Genome-Wide Data , 2014, bioRxiv.

[20]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[21]  Robyn L. Stanfield,et al.  Hepatitis C Virus E2 Envelope Glycoprotein Core Structure , 2013, Science.

[22]  T. Liang,et al.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis , 2013, Hepatology.

[23]  P. Simmonds,et al.  Modelling mutational and selection pressures on dinucleotides in eukaryotic phyla –selection against CpG and UpA in cytoplasmically expressed RNA and in RNA viruses , 2013, BMC Genomics.

[24]  Matti Pirinen,et al.  Imputation-Based Meta-Analysis of Severe Malaria in Three African Populations , 2013, PLoS genetics.

[25]  Barbara Rehermann,et al.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.

[26]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.

[27]  O. Delaneau,et al.  Supplementary Information for ‘ Improved whole chromosome phasing for disease and population genetic studies ’ , 2012 .

[28]  Z. Kutalik,et al.  Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. , 2012, Gastroenterology.

[29]  Ralf Bartenschlager,et al.  Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps* , 2012, The Journal of Biological Chemistry.

[30]  D. Burton,et al.  Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1 , 2012, Proceedings of the National Academy of Sciences.

[31]  J. Dubuisson,et al.  New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets , 2012, Gut.

[32]  C. Scagnolari,et al.  Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis , 2012, Virus Research.

[33]  F. Cosset,et al.  Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation , 2011, Expert Reviews in Molecular Medicine.

[34]  H. Drummer,et al.  The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. , 2011, The Journal of general virology.

[35]  F. Penin,et al.  Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2 , 2010, Journal of Virology.

[36]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[37]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[38]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[39]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[40]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[41]  Jon Wakefield,et al.  A Bayesian measure of the probability of false discovery in genetic epidemiology studies. , 2007, American journal of human genetics.

[42]  F. Penin,et al.  An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies , 2005, Journal of Virology.

[43]  P. Simmonds,et al.  Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.

[44]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[45]  J. Skehel,et al.  Interferon action—sequence specificity of the ppp(A2′p)nA-dependent ribonuclease , 1981, Nature.